Ultragenyx Pharmaceutical Inc.
Ultragenyx is a rare-disease biopharmaceutical company with minimal direct government dependence but significant regulatory exposure through FDA approval pathways and orphan drug incentives.
BusinessWhat RARE does
Ultragenyx develops and commercializes therapies for rare and ultra-rare genetic diseases, including enzyme replacement therapies and gene therapies. Revenue is primarily from product sales of approved rare-disease treatments, with a pipeline dependent on FDA breakthrough designations and orphan drug exclusivity.
Lifetime Government AwardsRARE federal contracts
RARE doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Smart Money · 13F HoldingsHedge funds holding RARE
Politicians Trading RAREMembers of Congress with recent RARE positions
Congressional TradesWho in Congress is trading RARE
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills to WatchLegislation flagged by our analysis
Political ProfileWhere RARE sits in Washington
Ultragenyx has minimal lobbying footprint and no identifiable congressional champions/critics. Stock movement driven primarily by clinical trial outcomes and FDA decisions rather than legislative events.
Regulatory ExposureThreats & opportunities
Regulatory threats
- FDA approval delays
- orphan drug exclusivity erosion
- Medicare price negotiation expansion
Regulatory opportunities
- orphan drug tax credit expansion
- breakthrough therapy designation acceleration
- rare disease research funding
Live signals + predictions for RARE — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades RARE
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord